Severe aortic valve disease is one of the major causes of cardiac death worldwide, whereas aortic valve replacement using a mechanical or biological valve substitute remains the gold standard treatment. 1 Biological valve substitutes have a number of clinical advantages over mechanical valves, including nonrequirement of anticoagulant therapy and absence of noise. However, structural deterioration remains the ''Achilles' heel'' of biologic prostheses because of the requirement for often complex reoperation and the associated morbidity and mortality confronting the patient. 2 Structural deterioration of biological valve substitutes consistently shows atherosclerosis-like inflammatory changes regardless of valve substitute types, 3, 4 indicating that common mechanisms or processes contribute to progressive valve failure, although factors related to the structural deterioration are not fully understood.
The aortic allograft is one of the alternative biological valve substitutes used in clinical practice over the last 50 years, 5, 6 although the use of the aortic allograft is not widely accepted because of the limited supply, variable implantation techniques contributing to uncertainty of the function, durability of the valve, 7 and prospect of a challenging reintervention. 8 At The Prince Charles Hospital, the cryopreserved aortic allograft has been implanted in a variety of patients as a treatment for severe aortic valve disease and has been the primary choice of valve substitute since 1975 when Queensland Heart Valve Bank was established to collect, prepare, store, and catalogue the allograft for implantation. 5 We explored the long-term outcomes of all patients after implantation of this single valve substitute, the ''aortic allograft.'' The aim was to identify factors influencing allograft durability and to explore putative mechanisms that may help to prevent or treat structural deterioration of biological valve substitutes.
MATERIALS AND METHODS Cohort and Data Collection
The prospective database contained 7973 aortic valve and root replacement surgeries performed in The Prince Charles Hospital between January 1975 and December 2008. The cryopreserved aortic allograft was used as the valve substitute in 852 cases (11%). Clinical progress of the patients was followed up with annual visits to the institutional or local physicians. Medical charts and referral letters, including serial echocardiographic studies, were reviewed to obtain the data, which were further supplemented by telephone interviews of patients under the care of distant physicians. Data collection was performed between January 2010 and June 2010. Mortality data also were gathered by request to the National Death Registry in December 2010. The study was approved by the institutional ethics committee (reference number HREC/09/QPCH/152).
Study End Points
A total of 285 allografts were surgically explanted by June 2010, and 288 patients died before removal of their aortic allograft, with explant and death defined as primary end points of this study. A further 267 patients who did not reach the primary end points were under continued follow-up until June 2010, and 12 patients were not contactable for or refused clinical assessment as of June 2010. Therefore, clinical follow-up was completed in 98.6% of total, consecutive cryopreserved aortic allografts in The Prince Charles Hospital. This gives an overall total of 840 allografts retrospectively studied from January 1975 to June 2010. Secondary end points assessed included other adverse cardiac events, such as structural/nonstructural failure and infection of the implanted allograft, which were defined according to the guideline. 9 
Treatment Strategies and Surgical Techniques
Surgical strategies in The Prince Charles Hospital to treat severe aortic valve disease have been consistently to replace the aortic valve using a mechanical or biological valve substitute. However, there were several evolutions through the study period. First, choice of the valve substitute has been modified according to the availability and the concerns related to the durability of the valve substitutes. 5 Until the early 1990s, the aortic allograft was the primary choice of valve substitute in any patient whose aortic annular anatomy was suitable for allograft implantation, regardless of the patient's age, although the use of the allograft was deferred in a number of patients because of limited availability or inadequate anatomy. In the mid to late 1990s, the use of the allograft was gradually limited by operating surgeons who were concerned about allograft durability. Since 2000, the aortic allograft has been used only in neonates, infants, small children, or patients with severe infective abscess in the aortic annulus.
Second, the pattern of aortic valve pathologies has gradually altered over the 3 decades in line with changes in the patient population. Rheumatic valvular disease was predominant in the first decade of the study, whereas endocarditis predominated in the last decade. Therefore, the characteristics and background of the cohort are substantially different among the eras of surgery (Table 1) . Finally, surgical techniques to implant the allograft have been markedly modified over the 3 decades (Table 2) . The subcoronary implantation technique was the surgical strategy in the first decade, when the allograft was sized 3 mm less than the valve annulus dimension. In the second decade, operating surgeons applied the full-root implantation technique, implanting an allograft sized the same as the native valve annulus dimension. This was done to achieve more consistent technical results to match congenital pathology with asymmetric annulus morphologies compared with the subcoronary technique, in which there is often difficulty in achieving perfect cusp alignment, resulting in some degree of incompetency. In addition, the intellect at this stage was to foster allograft integrity by maintaining the allograft valve in its natural position. In the process of this change, the inclusion-cylinder technique also was used, albeit briefly. Selection of the allograft was primarily dependent on the size of the native annulus, which was intraoperatively measured. No consistent attempt was made to match age, sex, or blood group.
No patients received immunosuppressive medications post-allograft implantation. Allograft infection was essentially treated in the same clinical manner as native aortic valve endocarditis, for which antibiotics were the first choice of treatment unless septic thromboembolism or large vegetation on the allograft was evident. 5 Reintervention for the allograft was indicated when the implanted allograft presented with structural/ nonstructural deterioration or medically uncontrollable infection, or the heart developed end-stage heart failure requiring cardiac transplantation.
Statistical Analyses
Continuous variables are presented as mean AE standard deviation or median (interquartile range). Categoric variables are shown as the percentage of the sample. Comparisons between the groups divided into the era of surgery were performed using 1-way analysis of variance followed by Dunn's multiple comparison test (Tables 1 and 2 ). Predictors of in-hospital mortality were identified using multivariate logistic regression, where potential predictors were those showing a P value less than .10 in a single variable analysis (Table E1) . Survival, freedom from structural deterioration, and freedom from allograft infection were estimated using the Kaplan-Meier method (Figures 1, 2 , and E1). Predictors of survival and structural deterioration were identified using a Cox proportional hazard model ( Table 3 ). The potential predictors in a multivariate Cox proportional hazard model were those with a P value less than .10 in a single variable model (Tables E2 and E3 ). Statistical analysis was performed with GraphPad Prism 4 (GraphPad Software Inc, La Jolla, Calif) and StatView-J 5.0 (SAS Institute Inc, Cary, NC).
RESULTS

In-Hospital Outcomes of Aortic Allograft Implantation
In-hospital mortality after aortic allograft implantation occurred in 21 patients (2.5%), including deaths in the operating room in 5 patients. A further 11 patients showed evidence of ventricular problems, with 9 having global dysfunction and 2 having tachyarrhythmia. Cerebrovascular accidents occurred in 3 patients, and overwhelming sepsis occurred in 2 patients. Risk factors of in-hospital mortality were older age, hypertension, smoking history, and New York Heart Association functional class III or IV (Table E1) .
Implantation of Aortic Allograft to Treat Active Infective Endocarditis
Aortic allografts were implanted in 101 patients to treat active endocarditis. Sixty-seven patients (66%) had a native aortic valve endocarditis, and 34 patients (34%) had an infection of a previously implanted valve substitute, such as a prosthesis in 23 patients and an allograft in 11 patients. The subcoronary technique was used in 33 cases of native endocarditis and 5 cases of valve substitute infection. In contrast, the full-root technique was used in 33 cases of native endocarditis and 29 cases of valve substitute
Abbreviation and Acronym
AS ¼ aortic stenosis infection. The inclusion-cylinder technique was used in 1 case of native endocarditis. Thus, 85% of valve substitute infection was treated by the full-root technique. As a result, 2 patients with native endocarditis and 2 patients with valve substitute infection died in the hospital. One patient with native endocarditis presented with suture line dehiscence, necessitating reintervention 8 days after allograft implantation.
Survival After Aortic Allograft Implantation
Of the 840 patients, 288 (34%) died without redo allograft surgery. Causes of late death were (1) allograftrelated cardiac arrests in 15 patients (5%), (2) other cardiac events in 44 patients (15%), (3) sudden, unexpected in 49 patients (17%), (4) noncardiac events in 134 patients (47%), and (5) unknown in 24 patients (8%). Estimated median survival post-allograft implantation was 11 years if age was 0 to 19 years at implantation, 24 years for those aged 20 to 39 years, 22 years for those aged 40 to 59 years, and 14 years for those aged 60 to 81 years ( Figure 1 ). Predictive factors of death were elderly age at surgery, preoperative serum creatinine greater than 150 mmol/L, preoperative New York Heart Association functional class III or IV, preoperative left ventricular ejection fraction less than 40%, and concomitant mitral valve surgery. Year of surgery, cause, or implantation method were not predictors of death (Tables E2 and E3 ).
Structural Deterioration of Aortic Allograft
Among the 840 patients, 266 (32%) developed structural deterioration with an estimated median time of 20 years post-implantation. Structural deterioration was defined as ''any change in function of an operated valve resulting from an intrinsic abnormality of the valve that causes stenosis or regurgitation exclusive of thrombosis or infection.'' 9 This definition was confirmed by the medical chart, which described the symptoms, physical examinations, echocardiography report, and reoperation record.
In the patients experiencing structural deterioration, 236 allografts (89%) were surgically explanted, and 13 patients (5%) are listed for reintervention. Fifteen patients (6%) died, and 2 patients (1%) had reintervention deferred because of comorbidities. Of the explants, 178 allografts were explanted in The Prince Charles Hospital. The pathology noted included a rupture of 1 or more leaflets in 123 patients (71%), poor leaflet coaptation in 5 patients (3%), and heavily calcified leaflets in 46 patients (26%). Of note, allografts in 2 patients have been functioning well for more than 30 years. These 2 patients were aged 28 years and 35 years at the time of surgery, both having a congenital aortic stenosis (AS), and underwent subcoronary implantation of the allograft retrieved from 20-year-old and 33-yearold donors, respectively. Both patients have not presented with any cardiovascular risk factors.
Structural deterioration was significantly related to the patient's age at operation (Figure 2 ). Estimated median time until structural deterioration was 11 years for those aged 10 to 19 years, 18 years for those aged 20 to 39 years, 19 years for those aged 40 to 59 years, and 21 years for those aged 60 to 81 years (P <.0001). The full-root and inclusion-cylinder implantation techniques had shorter times free from structural deterioration compared with the subcoronary technique (P <.001). The estimated median time until structural deterioration was 21 years after the subcoronary technique, 16 years after the full-root technique, and 18 years after the inclusion-cylinder technique. Results from the Cox model found risk factors influencing valve durability were elderly age, body mass index greater than 35 kg/m 2 , history of blood transfusion, donor aged more than 50 years, and the full-root technique (Tables 3 and E3 ). Blood group mismatch was not a significant risk factor for structural deterioration.
Echocardiographic studies for the 254 patients whose implanted allografts failed to show structural deterioration at the latest clinical follow-up identified moderate-severe AS in 3 patients, moderate AS in 12 patients, moderatesevere aortic incompetency in 11 patients, and moderate aortic incompetency in 47 patients; the median period to the echocardiographic study was 13 years, ranging from 169 days to 30 years. The other 181 patients showed mild or less stenosis or incompetency in the allograft.
Nonstructural Allograft Deterioration
Among the patients, 19 (2%) developed nonstructural deterioration, which was related to dehiscence of the suture line in 10, size or anatomy mismatch in 5, and others in 4, with the median period being 11 months ranging from 2 days to 18 years post-implantation. In this group, 13 allografts were implanted with the subcoronary method (68%), 5 allografts were implanted with the full-root method (26%), and 1 allograft was implanted with the inclusioncylinder method (5%).
New or Recurrent Infection of Implanted Allograft
Early infection of the implanted allograft (within 30 days post-implantation) developed in 2 patients (0.2%); of them, 1 patient developed septic shock related to allograft infection and eventually died at 18 days post-allograft implantation, and 1 patient developed staphylococcus infection in the allograft 14 days post-implantation and successfully underwent infected allograft explant and root replacement at 16 days. These 2 patients did not have a history of infective endocarditis preoperatively. On the other hand, 46 patients (5.5%) developed late infection with a median time of 5 years ranging from 4 months to 16 years post-allograft implantation. In this group, 7 died before reintervention, 27 allografts were explanted during the acute phase of allograft infection, and 12 infected allografts (25%) were successfully treated medically. Freedom from allograft infection at 10 years postimplantation was 88% in patients who had active endocarditis at the time of allograft implantation (n ¼ 101) and 95% in patients without a history of endocarditis (n ¼ 729) ( Figure E1 ).
Reintervention After Aortic Allograft Implantation
A total of 285 allografts (34%) were surgically explanted, and 216 (76%) were performed at The Prince Charles Hospital. Median time to reintervention was 12 years after the subcoronary method, 9 years after the full-root method, and 10 years after the inclusion-cylinder method. Surgical indications for the reintervention were structural deterioration in 169 patients, nonstructural deterioration in 19 patients, infection in 25 patients, and end-stage heart failure leading to cardiac transplantation in 3 patients. Of the 116 patients who had an allograft implanted with the subcoronary method, reintervention was achieved by replacing the aortic valve in only 89 (77%), replacing the aortic root in 24 (21%), and cardiac transplantation in 3 (3%). In contrast, of 91 patients who had an allograft implanted with the full-root method, reintervention was performed by replacing the allograft aortic valve in 23 (25%) and replacing the entire allograft root in 68 (75%). In-hospital mortality after reintervention occurred in 4 patients (2%), due to global myocardial dysfunction in 3 patients and persistent sepsis in 1 patient. Other in-hospital adverse cardiac events included cerebral infarction in 1 patient and persistent ventricular tachycardia in 1 patient.
DISCUSSION
This study documents the long-term outcomes after aortic allograft implantation for severe aortic valve disease, where 68% of 840 patients reached the primary end points of death or surgical explant of the implanted allograft. Most of the aortic allografts structurally deteriorated to predominantly produce valve incompetence over the 2 decades, significantly related to the young age of the recipient, elderly age of the donor, severe obesity in the recipient, history of blood transfusion, and full-root implantation. Nonstructural deterioration predominantly occurred after subcoronary implantation. Infection of the implanted allograft rarely occurred, whereas use of the allograft for active endocarditis was associated with a favorable outcome. Finally, in-hospital mortality for reintervention of the failed allograft was 2%, which is acceptable when compared with redo aortic valve replacement surgery.
The aortic allograft is hemodynamically an ideal valve substitute to replace a diseased aortic valve/root, because it consists of the same physiologic structure as the native aortic valve/root, which is known to perform extremely sophisticated functions. 10 Among a variety of reported allograft preparation methods, including fresh or homovital methods, The Queensland Heart Valve Bank established cryopreservation because it was shown to preserve viable valvular interstitial cells, 11 which play a major role in maintaining the normal valvular functions. However, it has been suggested that the valvular interstitial cells in the allograft might gradually develop necrosis or apoptosis, possibly by the host immune response, 4, 12, 13 leading to structural deterioration. However, our findings that allografts rarely deteriorate within 5 years and that half of allografts function well for more than 20 years suggest that these immune/inflammatory reactions are slow despite the absence of immunosuppressive drugs. Contemporary biological prosthetic valves, whose leaflets were processed from glutaraldehyde-treated xeno-tissue, have been shown to structurally deteriorate over 10 to 20 years, [14] [15] [16] essentially because of an atherosclerosislike inflammatory process. Given that biological prosthetic valves were implanted only in patients aged more than 60 years in these reports, the durability of the allografts, which was 20 years post-implantation on average in this study, is not shorter than that of contemporary biological prosthesis. Of note, patient-prosthesis mismatch, which is reportedly a cause of valve failure of biological prosthesis, 17 rarely occurs post-allograft implantation, 18 suggesting an advantage of the allograft over the biological prosthesis.
In addition to the previously reported risk factors, such as young age of the recipient or elderly age of the donor, this study identified that body mass index greater than 35 kg/m 2 and history of blood transfusion also were independent predictors of structural deterioration. Multiple inflammatory cytokines, which are systemically upregulated in severely obese patients, might lead to acceleration of the inflammation in the allograft. 19 Blood transfusion, which may be seen as a ''liquid organ transplant,'' activates the immune system to exacerbate the immune and inflammatory reaction against the allograft. 20 Of note, 2 allografts have been functioning well for more than 30 years. Both patients sustained a healthy lifestyle during the follow-up, as seen in the similar case reported by El-Hamamsy and colleagues. 21 This may suggest that the chronic inflammatory state associated with cardiovascular risk factors accelerates the structural deterioration of the allograft. Education of recipients regarding the benefits of a healthy lifestyle may be useful in an attempt to reduce the progression of structural deterioration of the biological valve substitute.
This study also suggests that subcoronary implantation is associated with reduced structural allograft deterioration when compared with full-root implantation. In contrast, previous reports, including one from our institution, showed that full-root implantation demonstrated durability similar to or greater than that observed for subcoronary implantation. 5, 22, 23 One should consider several reasons for such a contrary finding. First, previous reports analyzed risk factors for reintervention, whereas this study analyzed each pathology to clarify risk factors. Structural deterioration, which is the most dominant pathology leading to morbidity and mortality, developed less frequently after subcoronary implantation than after full-root implantation, whereas nonstructural deterioration rarely but predominantly occurred after subcoronary implantation. Second, aortic allografts in this study were cryopreserved, whereas allografts in other studies were prepared in a different fashion, such as the homovital method, 6 or in an often inconsistent manner. 22 Third, differences in follow-up period or analysis methods also may contribute to the contrary findings. No pathologic reason can be proffered to explain the finding that subcoronary implantation was more durable than full-root implantation, but one could postulate that the full-root technique leaves a larger amount of allograft wall tissues, which may therefore induce a heightened immune/inflammatory response compared with the subcoronary technique. In addition, the allograft implanted with a subcoronary technique, which is supported by the native aortic annulus that dynamically connects to ventricular motion, 10 could confront less mechanical stress than the allograft implanted with a full-root technique. However, there is difficulty in achieving perfect cusp alignment in the subcoronary technique, often resulting in some degree of incompetency without experience.
One of the most important indications for the use of the aortic allograft is currently active endocarditis involving the aortic root or annulus. 24 Predominant use of the full-root implantation procedure, which excludes extensive infective tissue in the pericardial space, may be a significant factor in producing favorable short-and long-term outcomes in this study. In addition, infection involving the implanted allograft, which included minimal prosthetic material, was medically treatable, similar to the native valve infection as shown in this study. It may thus be warranted that the aortic allograft is an ideal valve substitute in severe, acute aortic valve endocarditis, native or prosthetic. Moreover, the aortic allograft would be a good valve substitute for rheumatic valve disease, especially where there will be a scarred annulus and symmetric root. Therefore, the aortic allograft would have significant advantages over prosthetic material in geographic areas where medical support is not optimal when attempting to treat local or systemic infection, or where medical follow-up of the patients cannot be guaranteed.
Reintervention post-aortic allograft implantation is reportedly a surgical challenge because of severe calcific adhesion in the allograft and the surrounding tissue, including the coronary ostia. 8 However, in-hospital mortality of reintervention was only 2% in this study. The surgical strategy for which redo root replacement is essential after full-root implantation would consistently provide excellent results. 25 We believe that redo surgery after allograft implantation by the full-root technique is not well suited to transcatheter aortic valve replacement as an option, because the coronary ostia do not sit high after allograft implantation, although Khalpey and colleagues 26 recently reported that the valvein-valve procedure may be a good option for allograft failure.
Study Limitations
Some limitations in this study are related to the retrospective nature. The valve pathologies, the patient characteristics, and the implantation technique were markedly modified during the study period. In addition, the ''intent to care'' for evolving allograft regurgitation markedly changed over the study period. In the era of ''subcoronary'' implantation, the intent to treat moderate or less allograft regurgitation was to observe because it was considered to be stable, 5 whereas in the ''full-root'' era, the intent to treat allograft regurgitation was more aggressive, because the redo surgery after full-root implantation was complex, requiring sufficient patient and cardiac reserve to obtain satisfactory perioperative mortalities. Most important, evolution of the medical treatments, such as b-blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers, during the study period would have substantial effects on the patient outcome, in particular, on survival. Another limitation may include undefined cause of the mortality, although all the deaths were investigated by medical chart or death certificate. Development of coronary artery disease and corresponding treatment during the follow-up may have a substantial impact on survival.
CONCLUSIONS
The cryopreserved aortic allograft was durable for more than 15 years after implantation. The subcoronary implantation technique was more durable than the full-root technique, whereas the full-root technique was useful in treating active infective endocarditis. Patients with multiple cardiovascular risk factors or history of repeated blood transfusions may be less optimal candidates for allograft implantation, whereas encouraging patients to embrace a healthy lifestyle with appropriate medical care may prolong allograft durability. Reintervention for the implanted aortic allograft can provide favorable outcomes by using an appropriate surgical approach and technical proficiency.
Completion of the study allows an opportunity to reflect. At The Prince Charles Hospital, allograft use is now minimal except in special circumstances because of the technical difficulty associated with the reoperation. The current indications for allograft implantation are (1) endocarditis and (2) the young patient with a poor prospect for follow-up, given that the allograft's structural deterioration is slowly progressive; in both circumstances, the preference is for subcoronary implantation rather than the full-root technique. The factors associated with structural deterioration identified in this study provide important implications in the use of the biological valve prosthesis for valve disease, including transcatheter aortic valve replacement. .395
AI, Aortic insufficiency; AS, aortic stenosis; BMI, body mass index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
